IBE
print

Sprachumschaltung

Navigationspfad


Inhaltsbereich

Pfirrmann

1. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
J Natl Cancer Inst. 1998 Jun; 90(11):850-8.

2. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Loffler H, Pralle H, Queisser W, Tobler A. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Blood. 1999 Dec; 94(11):3668-77.

3. Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
Semin Hematol. 2003 Jan; 40(1):4-12.

4. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Leukemia. 2003 Aug; 17(8):1529-37.

5. Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia. 2003 Sep; 17(9):1820-6.

6. Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Leukemia. 2003 Dec; 17(12):2444-53.

7. Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Leukemia. 2004 Sep; 18(9):1460-7.

8. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov; 104(9):2667-74.

9. Pfirrmann M, Hasford J. A simulation study using validated prognostic factors to assess expected long-term survival.
Methods Inf Med. 2005 Apr; 44(4):577-83.

10. Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
Haematologica. 2005 Mar; 90(3):335-40.

11. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia. 2005 Jun; 19(6):984-9.

12. Maywald O, Pfirrmann M, Berger U, Breitscheidel L, Gratwohl A, Kolb HJ, Beelen DW, Tobler A, Metzgeroth G, Gnad SU, Hochhaus A, Hasford J, Hehlmann R, Reiter A. Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia. 2006 Mar; 20(3):477-84.

13. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood. 2007 Jun; 109(11):4686-92.

14. Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
Blood. 2007 Aug; 110(4):1283-90.

15. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Ann Oncol. 2009 Jan; 20(1):175-81.

16. Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Muller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Haematologica. 2009 Sep; 94(9):1227-35.

17. Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, Reichart B, Becker BF, Christ F. Shedding of the endothelial glycocalyx during cardiac surgery: on-pump versus off-pump coronary artery bypass graft surgery.
J Thorac Cardiovasc Surg. 2009 Dec; 138(6):1445-7.

18. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Blood. 2010 Mar; 115(10):1880-5.

19. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
Leukemia. 2011 Sep; 25(9):1433-8.

20. Stolzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhauser M, Rollig C, Kramer M, Mohr B, Oelschlagel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial.
Leukemia. 2011 Mar;25(3):420-8.

21. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hanel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-alpha in Newly Diagnosed Chronic Myeloid Leukemia.
J Clin Oncol. 2011 Apr; 29(12):1634-42.

22. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Blood. 2011 Jul; 118(3):686-92.

23. Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Blood. 2011 Dec; 118(26):6760-8.

24. Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C, Hasford J, Schaich M. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Lancet Oncol. 2012 Feb; 13(2):207-14.

25. Büchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Spath D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Dohner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M. Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm--Combined Prospective Analysis by the German AML Intergroup.
J Clin Oncol. 2012 Oct; 30(29):3604-10.

26. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Leukemia. 2012 Sep; 26(9):2096-102.

27. Lange T, Ernst T, Gruber FX, Maier J, Cross M, Muller MC, Niederwieser D, Hochhaus A, Pfirrmann M. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Haematologica. 2013 May; 98(5):714-7.

28. Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Leukemia. 2013 Oct; 27(10):2016-22.

29. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A. Comprehensive mutational profiling in advanced systemic mastocytosis.
Blood. 2013 Oct; 122(14):2460-6.


30. Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.
J Cancer Res Clin Oncol. 2014 Aug; 140(8):1367-81.

31. Kalmanti L, Saussele S, Lauseker M, Proetel U, Muller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Ann Hematol. 2014 Jan; 93(1):71-80.

32. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saussele S, Hochhaus A. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
J Clin Oncol. 2014 Feb 10; 32(5):415-23

33. Proetel U, Pletsch N, Lauseker M, Müller M, Hanfstein B, Krause S, Kalmanti L, Schreiber A, Heim D, Baerlocher G, Hofmann W-K, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Ann Hematol. 2014 Jul; 93(7):1167-76.

34. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Haematologica. 2014 Sep; 99(9):1441-7.

35. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014 Oct; 28(10):1988-92.

36. Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
J Cancer Res Clin Oncol. 2014 Nov; 140(11):1965-69.

37. Lauseker M, Hasford J, Hoffmann V, Müller M, Hehlmann R, Pfirrmann M. A multi-state model approach for prediction in chronic myeloid leukaemia.
Ann Hematol. 2015 Jun; 94(6):919-27.

38. Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Leukemia. 2015 May; 29(5):1123-32.

39. Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomaus A, Pezzutto A, Oppliger Leibundgut E, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Muller MC. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML-Study IV.
Blood. 2015 Jul; 126(1):42-9.

40. Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hanel M, Kohne CH, Lindemann HW, Berdel WE, Staib P, Muller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brummendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saussele S, Hehlmann R. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Ann Hematol. 2015 Dec; 94(12):2015-24.

41. Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R,Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia Leukemia. 2016 Jan; 30(1):48-56.

42. Gratwohl A*, Pfirrmann M*, Zander A, Kröger N, Beelen D, Nerl C, Novotny J, Scheid C, Spiekermann K, Mayer J, Sayer H, Falge C, Bunjes D, Doehner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer J, Ho A, Wilhelm M, Goebeler M, Lindemann H-W, Bormann M, Hertenstein B, Schlimok G, Baerlocher G, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld D, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Mueller M, Reiter A, Berger U, Saussele S, Hochhaus A, Hehlmann R. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia - A Randomized Comparison of Stem Cell Transplantation with Drug Treatment.
Leukemia. 2016 Mar; 30(3):562-69.
*Authors contributed equally, shared first authorship.

43. Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny H-P, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann W-K, Fabarius A, Cross N, Reiter A. Additional Mutations in SRSF2, ASXL1 and/or RUNX1 identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis. Leukemia. 2016 Jan; 30(1):136-143.

44. Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Leukemia. 2016 Jun; 30(6):1255-62.

45. Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M (2017) No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
J Cancer Res Clin Oncol. 2017, May; 143(5):843-50.

46. Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, Hehlmann R, Pfirrmann M for the German CML Study Group. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
Cancer. 2017, Jul; 123(13):2467-71.

47. Schutz C, Inselmann S, Sausslele S, Dietz CT, Muller MC, Eigendorff E, Brendel CA, Metzelder SK, Brummendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Leukemia. 2017 Apr; 31(4):829-36.


48. Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb H-J, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller M, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler M, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne C-H, Lindemann H-W, Waller C, Pfreundschuh M, Spiekermann K, Berdel W, Müller L, Edinger M, Mayer J, Beelen D, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Truemper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart M, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia. 2017 Nov; 31(11):2398-406.

49. Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Böhmer F-D. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
Oncotarget. 2018 Jan; 9(10):9442-55.

50. Hummel S, Beyerlein A, Pfirrmann M, Hofelich A, Much D, Hivner S, Bunk M, Herbst M, Peplow C, Walter M, Kohn D, Hummel N, Kratzsch J, Hummel M, Fuchtenbusch M, Hasford J, Ziegler A-G, Pinguin Study Group. Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study.
Mol Metab. 2018 Mar; 9:168-75.

51. Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann W-K, Mahon F-X, Saussele S. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk. 2018 Apr; 18(4):266-271.

52. Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause S, Hofmann WK, Hasford J, Pfirrmann M, Muller MC, Hochhaus A, Lauseker M. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Leukemia. 2018 May; 32(5):1222-1228.

53. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen J, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Stromberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machova Polakova K, Muller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M*, Mahon FX*, on behalf of the EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Lancet Oncol. 2018 Jun; 19(6):747-757.
*Authors contributed equally, shared senior authorship.

54. Rupprecht TA, Manz KM, Fingerle V, Lechner C, Klein M, Pfirrmann M*, Koedel U*. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis.
Clin Microbiol Infect. 2018 Dec; 24(12):1234-1240.
*Authors contributed equally, shared senior authorship.

55. Aklan B, Zilles B, Paprottka P, Manz K, Pfirrmann M, Santl M, Abdel-Rahman S, Lindner LH. Regional deep hyperthermia: quantitative evaluation of predicted and direct measured temperature distributions in patients with high-risk extremity soft-tissue sarcoma.
Int J Hyperthermia. 2019 Feb; 36(1):170-185.

56. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M for the International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
Leukemia. 2019 May; 33(5):1173-1183.

57. Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brummendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hanel M, Ho A, Dengler J, Falge C, Mohle R, Kremers S, Kneba M, Stegelmann F, Kohne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Muller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trumper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wundisch T, Geer T, Bildat S, Schafer E, Hasford J, Hehlmann R, Pfirrmann M. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica. 2019 May; 104(5):955-962.

CummuIativer Impact Factor (2017): 618.7